Despite concerns about the development of secondary T-cell malignancies due to CAR T-cell immunotherapy, experts still believed that the benefits outweigh the risks.
'In the countries where ibrutinib is indicated, this combination should be a new standard therapy for relapsed/refractory mantle cell lymphoma.'
'In patients with relapsed DLBCL in a complete remission, treatment with auto-HCT is associated with a lower rate of relapse/progression, and a longer progression-free survival [versus CAR T therapy].'
A new trial from Italy challenges a decades-old assumption that autologous stem cell transplant is more effective than radioimmunotherapy for consolidation after follicular lymphoma relapse.
CAR–T cell therapy for non-Hodgkin lymphoma appeared as safe and effective in patients with rheumatic autoimmune disease as in those without and also improved control of the underlying autoimmunity.